| 发明名称 |
METHODS FOR REDUCING THE RISK OF AN ADVERSE TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION IN MULTIPLE SCLEROSIS PATIENTS |
| 摘要 |
This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3). |
| 申请公布号 |
US2016030427(A1) |
申请公布日期 |
2016.02.04 |
| 申请号 |
US201514880777 |
申请日期 |
2015.10.12 |
| 申请人 |
SANOFI |
发明人 |
WEITZ Dietmar;MENGUY-VACHERON Francoise;CLOT Pierre-Francois;TURPAULT Sandrine |
| 分类号 |
A61K31/505;A61K31/167 |
主分类号 |
A61K31/505 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of providing teriflunomide wherein the teriflunomide is provided along with information indicating that it is useful for treating patients with relapsing forms of multiple sclerosis, and in cases said patients also receive treatment of rosuvastatin wherein rosuvastatin is co-administered with teriflunomide, reducing the dose of rosuvastatin to not exceeding 10 mg once daily is recommended. |
| 地址 |
Paris FR |
